Viridian Therapeutics, Inc.
VRDNNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $2.41B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $13.18$34.29
- Volume (live)
- -
- Avg. volume (3M)
- 2.05M
Viridian Therapeutics (VRDN) Stock Price & Financial Analysis
Viridian Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $21.92 - $22.75 |
|---|---|
| 52-Week High | $34.29 |
| 52-Week Low | $13.18 |
| Open | $22.75 |
| Volume (last close) | 1.18M |
| Average Volume (3M) | 2.05M |
| Revenue (TTM) | 71.13M |
|---|---|
| Net Income (TTM) | -386.97M |
| Free Cash Flow (TTM) | -335.04M |
| EPS (TTM) | −$4.11 |
| Profit Margin | -544.06% |
| Operating Margin | -569.68% |
| Return on Equity (ROE) | -58.45% |
| Debt to Equity | 0.37 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 2.41B |
|---|---|
| Shares Outstanding | 107.88M |
| Price to Sales (P/S) | 33.93 |
| Price to Book (P/B) | 3.65 |
| EV/EBITDA | -6.90 |
| 50-Day MA | $21.59 |
|---|---|
| 200-Day MA | $22.07 |
| 1-Year Change | +3.40% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Viridian Therapeutics at a Glance
As of the Oct 23, 2026 close, Viridian Therapeutics (VRDN) has a market capitalization of $2.41B. The stock trades at 33.9× sales. Over the trailing twelve months it lost $386.97M on revenue of $71.13M and burned $335.04M of free cash flow. Revenue grew 23220.3% year over year.
As of its latest reported balance sheet, it holds $164.99M in cash and securities against $242.88M of debt, a net debt position of $77.89M.
Viridian Therapeutics does not currently pay a dividend.
The share price is up 3.4% over the past year. At $22.37 (the Oct 23, 2026 close) it sits within its 52-week range of $13.18 to $34.29, above its 200-day moving average of $22.07.
Based on 12 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $34.11, 52.5% above the Oct 23, 2026 close.
Frequently Asked Questions About Viridian Therapeutics
What is the current stock price for VRDN?
As of the Oct 23, 2026 close, VRDN stock trades at $22.37. The 52-week range is $13.18–$34.29, with a day range of $21.92–$22.75.
What is the P/E ratio for VRDN?
The P/E ratio (Price-to-Earnings) for VRDN is shown in the Key Statistics section. This valuation metric helps compare Viridian Therapeutics, Inc. to industry peers.
Does VRDN pay dividends?
Viridian Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for VRDN?
Based on ratings from 12 professional analysts over the last 90 days, the consensus for VRDN is Buy. The average 12-month price target is $34.11, a 52.5% upside from the Oct 23, 2026 close of $22.37.
What is the market cap of VRDN?
As of the Oct 23, 2026 close, Viridian Therapeutics's market capitalization is $2.41B, classifying it as a mid-cap company. Viridian Therapeutics operates in the Healthcare sector within the Biotechnology industry.